Cada vez son más los centros de investigación que utilizan el poder de los sensores, los modelos avanzados y la inteligencia ...

Corvus rocketed higher today after it released Phase 1 soquelitinib data for treating eczema, showing excellent patient responses with no serious adverse events. Management plans to move on to a Phase ...

Clinical-stage biopharmaceutical company Corvus Pharmaceuticals (CRVS) priced an upsized underwritten public offering of .9M shares at $22.15 per share. Gross proceeds are expected to be ~$175M. The ...

An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.

Get the detailed quarterly/annual income statement for Corvus Pharmaceuticals, Inc. (CRVS). Find out the revenue, expenses and profit or loss over the last fiscal year.

Clinical trials and strong analyst support have fueled Corvus shares, but its future still hinges on key study results and avoiding funding pitfalls. Corvus Pharmaceuticals (NASDAQ: CRVS) is a ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. Chart does not reflect ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

IMDb.com, Inc. takes no responsibility for the content or accuracy of the above news articles, Tweets, or blog posts. This content is published for the entertainment of our users only. The news ...